RxGenomix training course to count as continuing education credit
RxGenomix's training program in Pharmacogenomics has been approved by the American Pharmacists Association as a continuing pharmacy education credit. Read More »
Rite Aid's Black Friday deals continue through the weekend
Rite Aid's Black Friday deals continue through the weekend. Read More »
PBMs save $941 per person according to new research
According a new research study conducted by Visante, pharmacy benefit managers are saving consumers and payers $941 on average per person a year. Read More »
Monroe named 2016 NACDS Foundation Excellence in Patient Care Award recipient
Centers for Disease Control and Prevention President and CEO Dr. Judith Monroe has received the 2016 NACDS Foundation Excellence in Patient Care Award. Read More »
Surgeon General's report discusses alcohol, drug abuse
A new report by the Surgeon General has discovered that alcohol and drug misuse and severe substance addiction is one of the nation’s crucial health concerns. Read More »
APhA celebrates anniversary of Immunization Certificate Training Program
The American Pharmacists Association recently released a video that commemorates its Pharmacy-based Immunization Certificate Training Program’s 20th anniversary. Read More »
Cigna asking medical groups to sign opioid pledge
Cigna is asking medical groups to join the effort of decreasing opioid use by 25 percent by signing a pledge to reduce opioid prescriptions and treat opioid abuse as a chronic condition. Read More »
Amgen, Janssen Biotech collaborate on multiple myeloma treatment
Amgen will partner with Janssen Biotech to assess the drug combination made up of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen, over the course of multiple clinical trials for the treatment of patients who have multiple myeloma. Read More »
Naloxone now available in Louisiana without prescription
Naloxone has been made available without the need for a prescription in all Walgreens pharmacy locations in the Louisiana. Read More »
ASHP accepting applications for Executive Residency program
The American Society of Health System Pharmacists is accepting applications for its 2017 ASHP Executive Residency in Association Leadership and Management. Read More »
AJHP launches redesigned website
The American Journal of Health-System Pharmacy has launched its redesigned website, AJHP.org. Read More »
Cigna releases ‘Holiday Survival Tips’
To kick off the holiday season, Cigna has released “Holiday Survival Tips.” Read More »
Omnicell to acquire Ateb and Ateb Canada
Omnicell has finalized an agreement for the acquisition of Ateb Inc. and its affiliate, Ateb Canada Ltd. Read More »
FDA approves Armodafinil Tablets in U.S.
The U.S. Food and Drug Administration has approved Armodafinil Tablets developed by Lupin Pharmaceuticals. Read More »
Biological Industries receives FDA approval for NutriStem
Biological Industries' Drug Master File for NutriStem hPSC XF Medium has been accepted by the U.S. Food and Drug Administration. Read More »
Otsuka ABILIFY MAINENA sNDA under review by FDA
Otsuka Pharmaceuticals and Lundbeck's supplemental New Drug Application for the expanded labeling of ABILIFY MAINENA has been completed and will receive a substantive review by the U.S. Food and Drug Administration. Read More »
Upsher-Smith has 3 poster presentations at AES annual meeting
Upsher-Smith Laboratories Inc. will have three poster presentations at the American Epilepsy Society’s 70th annual meeting, running through Tuesday in Houston. Read More »
Cigna to implement hi-tech approach to customer support
Cigna will be implementing an integrated hi-tech/hi-touch approach when it comes to the support and service of its customers. Read More »
Risankizumab granted Orphan Drug Designation by FDA
AbbVie's risankizumab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the investigational treatment of pediatric patients who have Crohn’s disease. Read More »
Eisai releases results of rufinamide study
Eisai Inc. has released the final results of its Phase 3 rufinamide study, an open-label, two-year investigation. Read More »
Alerts Sign-up